← Cheng Du Sheng Nuo Biotec Co. Ltd. A overview

Cheng Du Sheng Nuo Biotec Co. Ltd. A vs Shanghai Fosun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117.CG)

Q3 2026
▲3▼1

Strong first-half growth, then a bid-rigging charge clouds the outlook

  • First-half profit and revenue jumped about 50% Shengnuo Bio's first-half net profit rose 52% to 135 million yuan and revenue rose 50.3% to 507 million yuan, with second-quarter growth even faster. This shows the peptide drug business is expanding strongly, which supports a higher share price.

    The half-year report is the core new fundamental event that confirms rapid earnings growth.

  • Profit growth was backed by real cash and steady margins Operating cash flow rose 6.8% to 87 million yuan, gross margin stayed high at 58.7%, and return on equity was 11.8%. Cash-backed profit and healthy margins make the growth more believable and reduce the risk of a sharp negative reaction.

    It explains why the earnings growth is credible and not just accounting noise.

  • Subsidiary and controller indicted for bid-rigging A wholly owned subsidiary and the actual controller were indicted for colluding in national drug procurement bidding. The company already set aside 10.98 million yuan and expects fines that could cut future profit, and the case creates uncertainty about future sales of its finished drugs.

    This is the main new risk that can push the share price down and offset the strong earnings.

  • Early profit forecast set expectations for strong growth In July the company guided first-half net profit to rise 43% to 65% year on year. That early signal prepared investors for the strong result and helped support the stock before the full report arrived.

    It shows the market was already told growth would be strong, which frames the later report.

August 2026
▲3▼1

Strong first-half growth, then a bid-rigging charge clouds the outlook

  • First-half profit and revenue jumped about 50% Shengnuo Bio's first-half net profit rose 52% to 135 million yuan and revenue rose 50.3% to 507 million yuan, with second-quarter growth even faster. This shows the peptide drug business is expanding strongly, which supports a higher share price.

    The half-year report is the core new fundamental event that confirms rapid earnings growth.

  • Profit growth was backed by real cash and steady margins Operating cash flow rose 6.8% to 87 million yuan, gross margin stayed high at 58.7%, and return on equity was 11.8%. Cash-backed profit and healthy margins make the growth more believable and reduce the risk of a sharp negative reaction.

    It explains why the earnings growth is credible and not just accounting noise.

  • Subsidiary and controller indicted for bid-rigging A wholly owned subsidiary and the actual controller were indicted for colluding in national drug procurement bidding. The company already set aside 10.98 million yuan and expects fines that could cut future profit, and the case creates uncertainty about future sales of its finished drugs.

    This is the main new risk that can push the share price down and offset the strong earnings.

  • Early profit forecast set expectations for strong growth In July the company guided first-half net profit to rise 43% to 65% year on year. That early signal prepared investors for the strong result and helped support the stock before the full report arrived.

    It shows the market was already told growth would be strong, which frames the later report.

Latest
▲3▼1

Strong first-half growth, then a bid-rigging charge clouds the outlook

  • First-half profit and revenue jumped about 50% Shengnuo Bio's first-half net profit rose 52% to 135 million yuan and revenue rose 50.3% to 507 million yuan, with second-quarter growth even faster. This shows the peptide drug business is expanding strongly, which supports a higher share price.

    The half-year report is the core new fundamental event that confirms rapid earnings growth.

  • Profit growth was backed by real cash and steady margins Operating cash flow rose 6.8% to 87 million yuan, gross margin stayed high at 58.7%, and return on equity was 11.8%. Cash-backed profit and healthy margins make the growth more believable and reduce the risk of a sharp negative reaction.

    It explains why the earnings growth is credible and not just accounting noise.

  • Subsidiary and controller indicted for bid-rigging A wholly owned subsidiary and the actual controller were indicted for colluding in national drug procurement bidding. The company already set aside 10.98 million yuan and expects fines that could cut future profit, and the case creates uncertainty about future sales of its finished drugs.

    This is the main new risk that can push the share price down and offset the strong earnings.

  • Early profit forecast set expectations for strong growth In July the company guided first-half net profit to rise 43% to 65% year on year. That early signal prepared investors for the strong result and helped support the stock before the full report arrived.

    It shows the market was already told growth would be strong, which frames the later report.

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.CG)

Q3 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

August 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

Latest
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.